Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

lacopo Olivotto, MD

Professor of Cardiovascular Medicine
University of Florence and Meyer's Children Hospital
Florence, Italy

Disclosures

Iacopo Olivotto, MD, has the following relevant financial relationships:
Consultant or advisor for: Amicus Therapeutics, Inc.; Bristol Myers Squibb; Chiesi; Cytokinetics; Rocket Pharma; Sanofi Genzyme; Shire; Tenaya Therapeutics
Speaker or member of speakers bureau for: Amicus Therapeutics, Inc.; Bayer; Boston Scientific; Bristol Myers Squibb; Cytokinetics; Novartis; Sanofi Genzyme
Research funding from: Amicus Therapeutics, Inc.; Bayer; Boston Scientific; Bristol Myers Squibb; Chiesi; Cytokinetics; Novartis; Sanofi Genzyme

Steve R. Ommen, MD

Medical Director of the Mayo Hypertrophic Cardiomyopathy Clinic
Mayo Clinic
Rochester, Minnesota, United States

Disclosures

Steve R. Ommen, MD, has no relevant financial relationships.

J. Eduardo Rame, MD, MPhil, FAHA, FESC

Louis R. Dinon MD Professor of Medicine and Surgery
Director, Advanced Heart Failure and Cardiac Transplant
Enterprise Chief of Advanced Cardiac and Pulmonary Vascular Disease
Thomas Jefferson University
Philadelphia, Pennsylvania, United States

Disclosures

J. Eduardo Rame, MD, MPhil, FAHA, FESC, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb
Speaker or member of speakers bureau for: Bristol Myers Squibb

Jolanda van der Velden, PhD

Chair, Department of Physiology
Director, Amsterdam Cardiovascular Sciences Institute
Amsterdam University Medical Centre
Amsterdam, the Netherlands

Disclosures

Jolanda van der Velden, PhD, has no relevant financial relationships.

Editor

Grace O’Malley, PhD

Associate Medical Education Director, WebMD Global, LLC

Disclosures

Grace O’Malley, PhD, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

CME

Targeted Therapy in Hypertrophic Cardiomyopathy: A New Milestone for Patient Care

Authors: Iacopo Olivotto, MD; Steve R. Ommen, MD; J. Eduardo Rame, MD, MPhil, FAHA, FESC; Jolanda van der Velden, PhD
CME Released: 12/29/2022
Valid for credit through: 12/29/2023

Start Activity

Credits Available

Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, and surgeons.

The goal of this activity is for learners to be more familiar with myostatin inhibitors for the treatment of hypertrophic cardiomyopathy.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical data on emerging therapies for obstructive HCM
Have greater competence related to
- Implementing current guideline recommendations for the management of HCM
Demonstrate greater confidence in their ability to
- Use evidence-based recommendations for the management of HCM

Disclosures

Faculty

lacopo Olivotto, MD

Professor of Cardiovascular Medicine
University of Florence and Meyer's Children Hospital
Florence, Italy

Disclosures

Iacopo Olivotto, MD, has the following relevant financial relationships:
Consultant or advisor for: Amicus Therapeutics, Inc.; Bristol Myers Squibb; Chiesi; Cytokinetics; Rocket Pharma; Sanofi Genzyme; Shire; Tenaya Therapeutics
Speaker or member of speakers bureau for: Amicus Therapeutics, Inc.; Bayer; Boston Scientific; Bristol Myers Squibb; Cytokinetics; Novartis; Sanofi Genzyme
Research funding from: Amicus Therapeutics, Inc.; Bayer; Boston Scientific; Bristol Myers Squibb; Chiesi; Cytokinetics; Novartis; Sanofi Genzyme

Steve R. Ommen, MD

Medical Director of the Mayo Hypertrophic Cardiomyopathy Clinic
Mayo Clinic
Rochester, Minnesota, United States

Disclosures

Steve R. Ommen, MD, has no relevant financial relationships.

J. Eduardo Rame, MD, MPhil, FAHA, FESC

Louis R. Dinon MD Professor of Medicine and Surgery
Director, Advanced Heart Failure and Cardiac Transplant
Enterprise Chief of Advanced Cardiac and Pulmonary Vascular Disease
Thomas Jefferson University
Philadelphia, Pennsylvania, United States

Disclosures

J. Eduardo Rame, MD, MPhil, FAHA, FESC, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb
Speaker or member of speakers bureau for: Bristol Myers Squibb

Jolanda van der Velden, PhD

Chair, Department of Physiology
Director, Amsterdam Cardiovascular Sciences Institute
Amsterdam University Medical Centre
Amsterdam, the Netherlands

Disclosures

Jolanda van der Velden, PhD, has no relevant financial relationships.

Editor

Grace O’Malley, PhD

Associate Medical Education Director, WebMD Global, LLC

Disclosures

Grace O’Malley, PhD, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME

Targeted Therapy in Hypertrophic Cardiomyopathy: A New Milestone for Patient Care

Authors: Iacopo Olivotto, MD; Steve R. Ommen, MD; J. Eduardo Rame, MD, MPhil, FAHA, FESC; Jolanda van der Velden, PhDFaculty and Disclosures

CME Released: 12/29/2022

Valid for credit through: 12/29/2023

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

Earn Credit CME Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

lacopo Olivotto, MD

Steve R. Ommen, MD

J. Eduardo Rame, MD, MPhil, FAHA, FESC

Jolanda van der Velden, PhD

Editor

Grace O’Malley, PhD

Compliance Reviewer

Susan L. Smith, MN, PhD

CME

Targeted Therapy in Hypertrophic Cardiomyopathy: A New Milestone for Patient Care

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

lacopo Olivotto, MD

Steve R. Ommen, MD

J. Eduardo Rame, MD, MPhil, FAHA, FESC

Jolanda van der Velden, PhD

Editor

Grace O’Malley, PhD

Compliance Reviewer

Susan L. Smith, MN, PhD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Targeted Therapy in Hypertrophic Cardiomyopathy: A New Milestone for Patient Care